Health Care [ 10/12 ] | Biotechnology [ 46/75 ]
NASDAQ | Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 30, 26 | -0.84 Decreased by -27.27% | -0.80 Decreased by -5.00% |
| Nov 18, 25 | -0.88 Decreased by -1.15% | -0.80 Decreased by -10.00% |
| Aug 6, 25 | -0.87 Increased by +96.05% | -0.77 Decreased by -12.99% |
| May 8, 25 | -0.83 Increased by +44.30% | -0.62 Decreased by -33.87% |
| Mar 24, 25 | -0.66 | -0.58 Decreased by -13.79% |
| Nov 12, 24 | -0.87 | -0.63 Decreased by -38.10% |
| Aug 29, 24 | -22.00 | -4.40 Decreased by -400.00% |
| May 29, 24 | -1.49 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -20.77 M Decreased by -125.42% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -21.53 M Decreased by -23.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -21.25 M Decreased by -19.12% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -20.31 M Decreased by -45.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -9.21 M Increased by +23.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -17.47 M Decreased by -254.91% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -17.84 M Decreased by -58.13% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 251.00 K Decreased by -74.62% | -13.96 M Increased by +16.47% | Decreased by -5.56 K% Decreased by -229.11% |